Product
Dose escalation, first-in-human phase I clinical trial with an Expansion phase
1 clinical trial
1 indication
Indication
Metastatic Solid Tumor CancerClinical trial
Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid CancerStatus: Recruiting, Estimated PCD: 2024-12-31